Vaccination against nicotine: an emerging therapy for tobacco dependence
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Tobacco dependence is an addiction characterised by compulsive drug-seeking and drug-taking behavior and intensive craving in the absence of tobacco. Nicotine is the major addictive component of tobacco and acts on the reward system in the brain. Together with strong conditional reinforcements, unaided smoking cessation attempts are notoriously unsuccessful and even the most recently introduced pharmacotherapy, varenicline, only achieves a 23% continuous abstinence rate after 1 year. Vaccination against nicotine represents a promising novel concept for treating nicotine addiction. Antibodies against nicotine inhibit the passage of nicotine to brain and thus inhibit its addiction-reinforcing activities. There are three nicotine vaccines that are in clinical development. The first proof-of-concept study in smoking cessation with the vaccine NicQb (Cytos Biotechnology), a nicotine vaccine based on virus-like particles, demonstrated that continuous abstinence rates can be significantly increased by vaccination; however, as expected from the mode of action, a sufficient antibody level had to be achieved. Antibody level dependence of abstinence was also observed with the nicotine vaccine NicVAX (Nabi Biopharmaceuticals). Vaccination against nicotine has the potential of becoming an important therapy against tobacco dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“In a study comparing NRT, bupropion and placebo continuous abstinence rates after 12 months were 18% for the bupropion group, 10% for the group receiving nicotine patch and 6% for placebo [14] , which are in overall agreement with meta-analyses showing odds ratios of 1.”
ResultIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“On chronic daily exposure, plastic molecular alterations happen at the cellular level, such as the upregulation of receptors and changes in sensitivity that crucially contribute to the reinforcement of the addiction [8-10] .”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 2×
“Continuous abstinence rates between week 9 and week 52 in both trials were 22 – 23% for varenicline, 15 – 16% for bupropion and 8 – 10% for placebo [18,19] .”
BackgroundMethodOutcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 1×
“However, when given before nicotine, it attenuates nicotine-induced dopamine overflow, presumably by competitive binding [17] .”
BackgroundTonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · cited 3×
“There are two Phase III smoking cessation trials and one Phase III relapse prevention trial that have been published [18-20] .”
BackgroundMethodCo‐Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders
Kalman, D., Morissette, S. B., & George, T. P. (2005) · The American Journal on Addictions · doi:10.1080/10550490590924728 · Cited by 594
Symptoms of Tobacco Withdrawal: A Replication and Extension
Hughes, J. R. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250054007 · Cited by 449
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal
S. Watkins, G. F. K. (2000) · Nicotine & Tobacco Research · doi:10.1080/14622200050011277 · Cited by 424
Cited by
The contribution of vaccination to global health: past, present and future
Greenwood, B. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0433 · Cited by 979
Lifestyle risk factors for oral cancer
Petti, S. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2008.05.018 · Cited by 417
Smoking and asthma: dangerous liaisons
Polosa, R., & Thomson, N. C. (2013) · European Respiratory Journal · doi:10.1183/09031936.00073312 · Cited by 370
Self-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Metadata
- Authors
- Maurer, P., & Bachmann, M. F.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-10-30
- Volume
- 16
- Issue
- 11
- Pages
- 1775-1783
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2037494332
- Cited by
- 70
- References
- 16
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccination against nicotine: an emerging therapy for tobacco dependence. https://app.cochat.ai/papers/10.1517/13543784.16.11.1775
- The paper
- Maurer, P., & Bachmann, M. F. (2007). Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.11.1775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.